Artiva Biotherapeutics Inc. (ARTV) Stock Price, Quote & News

Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vascul...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 267 4467

Website: www.artivabio.com

Address:

5505 Morehouse Drive, Suite 100, San Diego, United States

RelentlessRider May. 9 at 9:51 AM

$ARTV Thinly traded speculative ticker with limited public operational visibility

0 · Reply

Papermoon347 May. 9 at 7:20 AM

$ARTV I made a ton of money with this ticker ,buy ,accumulate, hold and at least double in a year !

0 · Reply

focafoca99 May. 8 at 8:31 PM

$ARTV began a $300 million public offering of 23.9 million shares at $11.52 each, including pre‑funded warrants.

0 · Reply

dogood May. 8 at 2:36 PM

$ARTV watch $TRAW could break $2.5 anytime

0 · Reply

dogood May. 8 at 2:35 PM

$ARTV we should have been $22

0 · Reply

dogood May. 8 at 2:14 PM

$ARTV $13 would be awesome staying that for a while

0 · Reply

dogood May. 8 at 1:54 PM

$ARTV in my opinion it will stay between $12 and $13 for months

0 · Reply

dogood May. 8 at 1:53 PM

$ARTV already this should be at 22 because of offering now at $10

0 · Reply

dogood May. 8 at 1:52 PM

$ARTV give good data and publish offering , same bio criminals

0 · Reply

dogood May. 8 at 1:49 PM

$ARTV let’s go to $TRAW thsi will run not this guy

0 · Reply

Artiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright

2026-05-08T10:59:29.000Z - 2 days ago

Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)

May 8, 2026, 6:52 AM EDT - 2 days ago

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

2026-05-08T10:51:22.000Z - 2 days ago

Artiva reports data from clinical trials evaluating AlloNK

May 8, 2026, 6:31 AM EDT - 2 days ago

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 8, 2026, 6:30 AM EDT - 2 days ago

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Apr 15, 2026, 2:15 PM EDT - 25 days ago

Artiva Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 8:00 AM EDT - 4 weeks ago

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 10, 2026, 4:05 PM EDT - 2 months ago

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Mar 4, 2026, 1:10 PM EST - 2 months ago

Artiva Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 2 months ago

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

2026-02-24T13:23:47.000Z - 2 months ago

Artiva Biotherapeutics appoints Huston as Chief Financial Officer

Feb 24, 2026, 8:00 AM EST - 2 months ago

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

2026-02-19T13:17:45.000Z - 2 months ago

Artiva Biotherapeutics appoints Sorg to board of directors

Feb 19, 2026, 8:00 AM EST - 2 months ago

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

Jan 21, 2026, 8:00 AM EST - 3 months ago

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

Nov 18, 2025, 7:00 AM EST - 6 months ago

Artiva Biotherapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 11:30 AM EST - 6 months ago

Artiva Biotherapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 8:00 AM EST - 6 months ago

Artiva Biotherapeutics Transcript: Study Update

2025-11-12T12:36:40.000Z - 6 months ago

Artiva Biotherapeutics announces safety, translational data from AlloNK

Nov 12, 2025, 7:20 AM EST - 6 months ago

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

2025-11-12T12:05:30.000Z - 6 months ago

Artiva Biotherapeutics reports Q3 EPS (88c) vs (92c) last year

Nov 12, 2025, 7:00 AM EST - 6 months ago

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 3, 2025, 4:05 PM EST - 6 months ago

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Oct 30, 2025, 4:17 PM EDT - 6 months ago

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

2025-10-17T13:16:24.000Z - 7 months ago

Why Is Artiva Biotherapeutics Stock (ARTV) Up 105% Today?

2025-10-17T12:00:36.000Z - 7 months ago

Artiva Biotherapeutics price target raised to $23 from $18 at Wedbush

$Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update$

Oct 16, 2025, 4:05 PM EDT - 7 months ago

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Sep 3, 2025, 9:45 AM EDT - 8 months ago

Artiva Biotherapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 25, 2025, 4:05 PM EDT - 9 months ago

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

2025-08-06T21:21:24.000Z - 9 months ago

Artiva Biotherapeutics files $300M mixed securities shelf

Aug 6, 2025, 4:05 PM EDT - 9 months ago

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

2025-06-11T10:21:17.000Z - 11 months ago

Artiva Biotherapeutics assumed with a Buy at H.C. Wainwright

Jun 4, 2025, 9:20 AM EDT - 1 year ago

Artiva Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

2025-05-13T21:05:16.000Z - 1 year ago

Artiva Biotherapeutics announces new, long-term data for AlloNK combination

May 13, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

2025-05-08T12:41:18.000Z - 1 year ago

Artiva Biotherapeutics reports Q1 EPS (83c) vs. ($17.24) last year

2025-05-08T12:40:47.000Z - 1 year ago

Artiva Biotherapeutics sees cash runway into 2Q27

May 8, 2025, 8:00 AM EDT - 1 year ago

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

Apr 28, 2025, 4:35 PM EDT - 1 year ago

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

2025-04-09T16:15:40.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

BMY IBIO LXEO RYTM TPST

2025-04-08T20:45:35.000Z - 1 year ago

Artiva CMO Thorsten Graef switches to advisor role, Subhashis Banerjee succeeds

BMY

Apr 8, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Apr 7, 2025, 11:00 AM EDT - 1 year ago

Artiva Biotherapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

2025-03-25T18:36:19.000Z - 1 year ago

Artiva Biotherapeutics price target lowered to $20 from $23 at Cantor Fitzgerald

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 5, 2025, 2:30 PM EST - 1 year ago

Artiva Biotherapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Jan 29, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Nov 20, 2024, 10:30 AM EST - 1 year ago

Artiva Biotherapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 11, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 18, 2024, 7:08 PM EDT - 1 year ago

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

RelentlessRider May. 9 at 9:51 AM

$ARTV Thinly traded speculative ticker with limited public operational visibility

0 · Reply

Papermoon347 May. 9 at 7:20 AM

$ARTV I made a ton of money with this ticker ,buy ,accumulate, hold and at least double in a year !

0 · Reply

focafoca99 May. 8 at 8:31 PM

$ARTV began a $300 million public offering of 23.9 million shares at $11.52 each, including pre‑funded warrants.

0 · Reply

dogood May. 8 at 2:36 PM

$ARTV watch $TRAW could break $2.5 anytime

0 · Reply

dogood May. 8 at 2:35 PM

$ARTV we should have been $22

0 · Reply

dogood May. 8 at 2:14 PM

$ARTV $13 would be awesome staying that for a while

0 · Reply

dogood May. 8 at 1:54 PM

$ARTV in my opinion it will stay between $12 and $13 for months

0 · Reply

dogood May. 8 at 1:53 PM

$ARTV already this should be at 22 because of offering now at $10

0 · Reply

dogood May. 8 at 1:52 PM

$ARTV give good data and publish offering , same bio criminals

0 · Reply

dogood May. 8 at 1:49 PM

$ARTV let’s go to $TRAW thsi will run not this guy

0 · Reply

lordbealish May. 8 at 1:49 PM

$ARTV be like 🤣🤣

0 · Reply

AngelCapital May. 8 at 1:36 PM

$ARTV down to 11.55 open Bingo

0 · Reply

AngelCapital May. 8 at 1:33 PM

$ARTV short 14 Covered 12 $20K profit done for today

0 · Reply

STACKD0E May. 8 at 1:27 PM

$ARTV $NRXP $AIIO $ALGS

0 · Reply

StocktwitsNews May. 8 at 1:10 PM

ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy $ARTV https://stocktwits.com/news/equity/markets/artiva-artv-stock-gains-arthritis-therapy-update-300m-fund-raising/cZX2mO2ReX6

0 · Reply

lordbealish May. 8 at 1:06 PM

$ARTV slowly to 17

0 · Reply

goldoversilver May. 8 at 12:55 PM

$ARTV long term hold imo up down sideways idc. Im holding

1 · Reply

JFais May. 8 at 12:38 PM

$ARTV (NP) Nice to see AlloNK making a comeback 71% ACR50 in refractory RA patients, no relapses with 6 months follow-up. Alignment with FDA on single phase 3 vs rituximab + $300M private placement to power forward >70 patients treated, responses also observed in SjD and SSc

0 · Reply

AngelCapital May. 8 at 12:36 PM

$ARTV going red open

0 · Reply

AngelCapital May. 8 at 12:35 PM

$ARTV 12 come

0 · Reply

AngelCapital May. 8 at 12:28 PM

$ARTV no buyer. No one buying at this price until 11 range buying offering

0 · Reply

AngelCapital May. 8 at 12:18 PM

$ARTV surprisingly volumn ugly Wait market open dump

0 · Reply

Market Cap	N/A
Revenue (ttm)	33.49M
Net Income (ttm)	-27.70M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	342,500
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	Strong Buy
Price Target	N/A